SENZA Stock Overview
Provides non-animal tests for assessing a substance’s allergenicity. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
SenzaGen AB Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 5.22 |
| 52 Week High | SEK 9.50 |
| 52 Week Low | SEK 3.86 |
| Beta | 0.30 |
| 1 Month Change | -0.76% |
| 3 Month Change | -11.53% |
| 1 Year Change | -39.72% |
| 3 Year Change | -34.42% |
| 5 Year Change | -68.17% |
| Change since IPO | -87.94% |
Recent News & Updates
Recent updates
We Think Shareholders Are Less Likely To Approve A Pay Rise For SenzaGen AB's (STO:SENZA) CEO For Now
May 08
Shareholders Will Probably Hold Off On Increasing SenzaGen AB's (STO:SENZA) CEO Compensation For The Time Being
May 09We're Not Very Worried About SenzaGen's (STO:SENZA) Cash Burn Rate
Nov 28We're Hopeful That SenzaGen (STO:SENZA) Will Use Its Cash Wisely
Jul 30Companies Like SenzaGen (STO:SENZA) Are In A Position To Invest In Growth
Apr 16Here's Why We're Not Too Worried About SenzaGen's (STO:SENZA) Cash Burn Situation
Jan 01Shareholder Returns
| SENZA | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | 0.4% | -0.2% | 1.1% |
| 1Y | -39.7% | -9.1% | -4.6% |
Return vs Industry: SENZA underperformed the Swedish Biotechs industry which returned -9.1% over the past year.
Return vs Market: SENZA underperformed the Swedish Market which returned -4.6% over the past year.
Price Volatility
| SENZA volatility | |
|---|---|
| SENZA Average Weekly Movement | 10.9% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in SE Market | 13.8% |
| 10% least volatile stocks in SE Market | 4.3% |
Stable Share Price: SENZA's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: SENZA's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of Swedish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2010 | 34 | Peter Nahlstedt | senzagen.com |
SenzaGen AB provides non-animal tests for assessing a substance’s allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; GARD air: respiratory sensitization assessment, and the GARD® technology. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, skin sensitization medical device services; tailored advisory services for medical devices; and substance based medical devices.
SenzaGen AB Fundamentals Summary
| SENZA fundamental statistics | |
|---|---|
| Market cap | SEK 154.01m |
| Earnings (TTM) | -SEK 18.89m |
| Revenue (TTM) | SEK 57.02m |
Is SENZA overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SENZA income statement (TTM) | |
|---|---|
| Revenue | SEK 57.02m |
| Cost of Revenue | SEK 18.81m |
| Gross Profit | SEK 38.20m |
| Other Expenses | SEK 57.09m |
| Earnings | -SEK 18.89m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
Aug 20, 2025
| Earnings per share (EPS) | -0.64 |
| Gross Margin | 67.01% |
| Net Profit Margin | -33.13% |
| Debt/Equity Ratio | 1.8% |
How did SENZA perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/06/01 10:58 |
| End of Day Share Price | 2025/05/30 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
SenzaGen AB is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Peter Sellei | Penser Access |
| Klas Palin | Penser Access |